Multiorgan procurement increases systemic inflammation in brain dead donors. (27th June 2013)

• Record Type: Journal Article
• Authors: Auråen, Henrik; Mollnes, Tom E.; Bjørtuft, Øystein; Bakkan, Per A.; Geiran, Odd; Kongerud, Johny; Fiane, Arnt; Holm, Are M.
• Is Part Of: Clinical transplantation. Volume 27:Number 4(2013:Jul./Aug.)
• Page Start: 613
• Page End: 618
• Publication Date: 2013-06-27
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12175
• Languages: English
• ISSNs: 0902-0063

Abstract

<abstract abstract-type="main" id="ctr12175-abs-0001"> <title>Abstract</title> <p>Organs available for solid organ transplantation are mainly procured from brain dead donors. The inflammation associated with brain death may reduce organ quality and increase organ immunogenicity, thus leading to inferior recipient outcome. We hypothesized that the extensive surgical procedure performed during multiorgan procurement enhances the levels of systemic inflammatory biomarkers. We measured the levels of 27 cytokines and the terminal complement complex (TCC) in plasma samples from brain dead organ donors (n = 34) drawn before and at three specific time points during procurement surgery. Baseline levels of G‐CSF, interferon‐γ, IL‐1ra, IL‐4, IL‐6, IL‐7, IL‐8, IL‐10, IP‐10, MCP‐1, macrophage inflammatory protein (MIP)‐1β, platelet derived growth factor (PDGF), regulated upon activation T cell expressed and secreted, and tumor necrosis factor‐α were significantly elevated in brain dead donors compared with normal individuals (n = 14), but they were not associated with time on ventilator or any other registered clinical variable. Notably, the secretion of G‐CSF, IL1‐ra, IL‐6, IL‐8, IL‐10, IP‐10, MCP‐1, MIP‐1β, PDGF, and TCC, the latter reflecting ongoing complement activation, increased significantly during surgery. None of the biomarker increases were correlated with operation duration. Multiorgan procurement surgery significantly adds to the inflammatory response revealed by both pro‐ and anti‐inflammatory biomarkers associated with brain death. Future studies should determine whether this is associated with inferior recipient outcome.</p> </abstract>